MALDI-TOF mass spectrometry proteomic profiling to discriminate response to the combination of bevacizumab and erlotinib in non-small cell lung cancer (NSCLC).

被引：0
|
作者：
Salmon, JS
Sandler, A
Billheimer, D
Herbst, RS
Tran, HT
Tsao, A
Dang, TP
机构：
[1] Vanderbilt Univ Sch Med, Nashville, TN USA
[2] MD Anderson Canc Ctr, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：626S / 626S
页数：1
相关论文
共 50 条
  • [41] Bevacizumab in non-small cell lung cancer
    Sandler, Alan
    CLINICAL CANCER RESEARCH, 2007, 13 (15) : 4613S - 4616S
  • [42] A multicenter phase II study of sorafenib in combination with erlotinib patients with advanced non-small cell lung cancer (NSCLC)
    Cho, B.
    Kim, S.
    Heo, D. S.
    Kang, S.
    Kim, H.
    Lee, D.
    Kim, D.
    Jung, M.
    Choi, J.
    Kim, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [43] Sunitinib in Combination With Erlotinib for the Treatment of Advanced/Metastatic Non-small Cell Lung Cancer (NSCLC): a Phase III Study
    Govindan, R.
    Krzakowski, M. J.
    Szczesna, A.
    Strausz, J.
    Makhson, A. N.
    Reck, M.
    Tye, L.
    Zhang, K.
    Chao, R. C.
    Scagliotti, G. V.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S557 - S557
  • [44] Panel Based MALDI-TOF Tumour Profiling Is a Sensitive Method for Detecting Mutations in Clinical Non Small Cell Lung Cancer Tumour
    Sherwood, James L.
    Mueller, Susanne
    Orr, Maria C. M.
    Ratcliffe, Marianne J.
    Walker, Jill
    PLOS ONE, 2014, 9 (06):
  • [45] Promotor-methylation profiling in lung cancer using MALDI TOF mass spectrometry
    Ehrich, M
    Liloglou, T
    Field, J
    Nelson, M
    van den Boom, D
    LUNG CANCER, 2005, 49 : S18 - S18
  • [46] Genomic profiling and sites of metastasis in non-small cell lung cancer (NSCLC)
    Chan, Kok Hoe
    Lin, Ji
    Sridhar, Arthi
    Jafri, Syed H.
    CANCER RESEARCH, 2023, 83 (07)
  • [47] Erlotinib in non-small cell lung cancer: a review
    Blackhall, FH
    Rehman, S
    Thatcher, N
    EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (06) : 995 - 1002
  • [48] Erlotinib in the treatment of non-small cell lung cancer
    Brown, Ewan R.
    Shepherd, Frances A.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2005, 5 (05) : 767 - 775
  • [49] In vivo assessment of the effects of bevacizumab in advanced non-small cell lung cancer (NSCLC)
    Heist, R. S.
    Duda, G. D.
    Sahani, D.
    Pennell, N. A.
    Neal, J. W.
    Ancukiewicz, M.
    Engelman, J. A.
    Lynch, T. J.
    Jain, R. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [50] Enhanced FGFR signaling correlates with erlotinib/bevacizumab response in advanced non-squamous non-small cell lung cancer
    Franzini, Anca
    Baty, Florent
    Brutsche, Martin
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
12345